Skip to Main Content

Author Details

Thomas John
Peter MacCallum Cancer Centre
1973
228
42
PMIDPaper TitleJournal TitlePublished Year
36822606When research becomes practice: the concept of the therapeutic misconception and challenges to consent in clinical trials.Intern Med J2023
37663675Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective.JTO Clin Res Rep2023
37550943Breathing in danger: how particulate matter pollution is putting the public at risk of lung cancer<sup>â¿ </sup>.J Pathol2023
37573702Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results.Lung Cancer2023
37348991Rethinking Biomarkers for Combination Chemoimmunotherapy.J Thorac Oncol2023
37143952Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review.Front Oncol2023
37077199LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.JTO Clin Res Rep2023
37406824PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.Int J Radiat Oncol Biol Phys2023
37336620Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set.BMJ Open Respir Res2023
37272535Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC.N Engl J Med2023
37236398Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.J Thorac Oncol2023
37365486Patterns of care for people with small cell lung cancer in Victoria, 2011-19: a retrospective, population-based registry data study.Med J Aust2023
36720083Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.J Clin Oncol2023
36849516Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.Nat Commun2023
36811822Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.Pharmacoecon Open2023
36543429Safety of Dueling NSCLC With Dual Agent Immunotherapy.J Thorac Oncol2023
36871487First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.Eur J Cancer2023
36572732Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.Br J Cancer2023
36534268Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast.Target Oncol2023
34740861Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.J Thorac Oncol2022
35343573Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.Biochem Soc Trans2022
35663414Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC.JTO Clin Res Rep2022
35393508Imaging immunity in patients with cancer using positron emission tomography.NPJ Precis Oncol2022
35553647Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.Clin Cancer Res2022
36400733ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.BMJ Open2022
36130865Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.Clin Lung Cancer2022
35958323Expert consensus on perioperative treatment for non-small cell lung cancer.Transl Lung Cancer Res2022
34922050Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.Cancer Epidemiol2022
35156837PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.Future Oncol2022
35099823Loss of STING expression is prognostic in non-small cell lung cancer.J Surg Oncol2022
35012927Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.Clin Cancer Res2022
35182247First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.Int J Clin Oncol2022
35090047Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.Cancer2022
35176458ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.Ann Oncol2022
35144967Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.Clin Cancer Res2022
32778511Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.Clin Lung Cancer2021
33795785Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.Sci Rep2021
33647577Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.Lung Cancer2021
34864501Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].ESMO Open2021
34496934Correction to: Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.Hered Cancer Clin Pract2021
34607285First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.ESMO Open2021
34399810Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.Hered Cancer Clin Pract2021
34723634A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.Future Oncol2021
34629863Keyhole Anterior Lamellar Keratoplasty for Boston Keratoprosthesis Corneal Melt.Clin Ophthalmol2021
34131107Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.Cell Death Discov2021
34127383EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.Clin Lung Cancer2021
34295682Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.Transl Lung Cancer Res2021
34295683Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation.Transl Lung Cancer Res2021
34295676A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.Transl Lung Cancer Res2021
34295674Immunotherapy in oncogene addicted non-small cell lung cancer.Transl Lung Cancer Res2021
  • 1 - 50 of 228

Recommended Authors

Grace S Ahn
University of California San Diego
Career Start Year 2017
Number of shared co-authors 0
Kaitlin C McLoughlin
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 0
Jonathan W Rick
University of Arkansas for Medical Sciences
Career Start Year 2015
Number of shared co-authors 0
Yi Zhao
the First Affiliated Hospital of Guangzhou Medical University
Career Start Year 2013
Number of shared co-authors 1
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 3
Sara Kuruvilla
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2010
Number of shared co-authors 4
Matthew J Cecchini
Western University
Career Start Year 2008
Number of shared co-authors 1
Pankaj Vats
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2008
Number of shared co-authors 0
Jaclyn LoPiccolo
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 1
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 9
Mark E Smolkin
University of Virginia
Career Start Year 2002
Number of shared co-authors 0
Dexiang Gao
University of Colorado Anschutz Medical Campus
Career Start Year 2001
Number of shared co-authors 2
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 2
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 2
Woo Young Kim
Westchester Medical Center
Career Start Year 1998
Number of shared co-authors 1
Sung Tae Kim
Busan Paik Hospital, Inje University
Career Start Year 1996
Number of shared co-authors 3
Nam Bui
Stanford University
Career Start Year 1996
Number of shared co-authors 0
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Shekhar Ghamande
Texas A&M University College of Medicine
Career Start Year 1995
Number of shared co-authors 0
Dong Wook Kim
Yonsei University College of Medicine, Republic of Korea S. Biomedics Co.
Career Start Year 1992
Number of shared co-authors 0
Vera J Suman
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 1
Borko Jovanovic
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Career Start Year 1991
Number of shared co-authors 0
Kyoung-Mee Kim
Seoul National University College of Medicine
Career Start Year 1991
Number of shared co-authors 3
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Martine Antoine
Erasme University Hospital, Universite Libre de Bruxelles
Career Start Year 1989
Number of shared co-authors 0
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 4
Phuong Nguyen
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 0
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 8
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 7

Collaborators

Paul Mitchell
Olivia Newton-John Cancer Research Institute
Co-authored papers 24
Frances A Shepherd
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 18
Bibhusal Thapa
Northern Hospital
Co-authored papers 15
Puey Ling Chia
Lee Kong Chian School of Medicine, Nanyang Technological University
Co-authored papers 14
Marzena Walkiewicz
Olivia Newton-John Cancer Research Institute
Co-authored papers 14
Prudence A Russell
St Vincent's Hospital
Co-authored papers 13
Ming-Sound Tsao
University Health Network, University of Toronto
Co-authored papers 13
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Co-authored papers 12
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 12
Paul C Boutros
University of California los angeles
Co-authored papers 10
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Co-authored papers 9
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 8
Carmel Murone
Olivia Newton-John Cancer Research Institute
Co-authored papers 8
Gareth Rivalland
Auckland City Hospital
Co-authored papers 8
Roy S Herbst
Yale School of Medicine
Co-authored papers 8
Maud H W Starmans
Ontario Institute for Cancer Research
Co-authored papers 6
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Co-authored papers 6
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Co-authored papers 6
Gavin M Wright
St. Vincent's Hospital, University of Melbourne
Co-authored papers 6
Stephen Barnett
Royal Melbourne Hospital
Co-authored papers 6
Khashayar Asadi
Austin Hospital
Co-authored papers 6
Simon Knight
Churchill Hospital
Co-authored papers 6
Alexander Drilon
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Marliese Alexander
Department of Pharmacy, 5Peter MacCallum Cancer Centre
Co-authored papers 5
John M Mariadason
Olivia Newton-John Cancer Research Institute
Co-authored papers 4
Ming Li
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Naoki Yanagawa
Yamagata Prefectural Central Hospital
Co-authored papers 4
Igor Jurisica
Schroeder Arthritis Institute
Co-authored papers 4
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Co-authored papers 4
Otavia L Caballero
Ludwig Institute for Cancer Research Ltd.
Co-authored papers 3
Release 1.2